Research
    Jun Ma
    Title Professor and Deputy President
    Profile
    Jun Ma is a professor of Radiation Oncology and deputy president of Sun Yat-sen University Cancer Center, and director of the Key Laboratory of Multidisciplinary Diagnosis and Treatment of Nasopharyngeal Carcinoma, Guangzhou, China. Prof. Ma graduated from Hu Nan Medical University, Changsha, China in 1985, and gained his M.D. from Sun Yat-sen University of Medical Sciences, Guangzhou, China in 1990. He subsequently completed a 2-year postdoctoral fellowship program in Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
     
    The main research interest of Prof. Ma is prognosis prediction and comprehensive treatment of nasopharyngeal carcinoma. He has done a solid job in improving the TNM staging system and investigating novel therapeutic strategies for nasopharyngeal carcinoma. He has been the Principal or Co-Principal Investigator of several multi-center clinical trials and translational research projects, including two Key Clinical Projects from the Ministry of Health (2007-2009 & 2011-2013).
     
    He also serves as a reviewer and member of the editorial boards of many peer-reviewed journals. As the first author and/or corresponding author, Prof. Ma has published over 48 papers in prestigious, international peer-reviewed journals, such as Lancet Oncol, J Clin Oncol, Clin Cancer Res, Cancer, Radiology, Radiother Oncol, and Int J Radiat Oncol Biol Phys. He has received the “Chinese Medical Science and Technology Award” (2007), “National Science and Technology Progress Award” (2009), “Guangdong Province Dingying Science & Technology Progress Award” (2009) and “JiePing Wu-Paul Janssen Medical & Pharmaceutical Award” (2013). He was honored as “China Medical Board (CMB) Distinguished Professor”, “the Outstanding Expert of the Ministry of Health of China” and “Distinguished Professor of Guangdong Province Universities and Colleges Pearl River Scholar”.
    Email majun@sysucc.org.cn
    Phone 020-87343469
    Research Interest(s) Radiation therapy and comprehensive treatment of NPC.
    Education

    1. Sun Yat-Sen University of Medical Sciences (SUMS) June1990, Master degree of Oncology, Canton, China 

    2. Hu Nan Medical UniversityJune 1985, Doctoral degree in Medicine, Hunan, China

    Publications

    1. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J (corresponding author). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163-171. (IF 25.1) 

    2. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho William, Yun JP, Zeng J, Liu LZ, Guo Y, Wang HY, Ma J (corresponding author). Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633-641. (IF 25.1) 

    3. Ma J ((first author, corresponding author), Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a Prospective Randomized Trial Comparing Neoadjuvant Chemotherapy plus Radiotherapy versus Radiotherapy-alone in Patients with Locoreginally Advanced Nasopharyngeal Carcinoma. J Clin Oncol.2001;19(5):1350-1357.(IF 18.0)

    4. Chua DT, Ma J (joint first author), Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ. Long-term Survival after Cisplatin-based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase Ⅲ Trials. J Clin Oncol. 2005;23(6):1118-1124.( IF 18.0)

    5. Ma J(first author, corresponding author), Liu L, Tang L, Zong J, LinA, Lu T, Cui N, Cui C, Li L. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13 (5): 1445-1452.( IF 7.8) 

     6. Mao YP, Liang SB, Liu LZ, Chen Y, Sun Y, Tang LL, Tian L, Lin AH, Liu MZ, Li L, Ma J (corresponding author). The N-staging System in Nasopharyngeal Carcinoma with RTOG Guidelines for Lymph Node Levels Based on Magnetic Resonance Imaging. Clin Cancer Res.2008;14(22):7497-7503.( IF 7.8)

    7. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J (corresponding author). The Prognostic Value and Staging Categories of Anatomical Masticator Space Involvement in Nasopharyngeal Carcinoma: A study of 924 cases based on magnetic resonance imaging. Radiology. 2010;257(1):151-157. (IF 6.3)

    8. Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, Cho WC, Liu LZ, Li L, Ma J (corresponding author). A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngealcarcinoma. Int J Cancer, 2014; 134: 1359-1368. (IF 6.2)

     9. Tang LL, Li L, Mao YP, Liu LZ, Liang SB, Chen Y, Sun Y, Liao XB, Tian L, Lin AH, Liu MZ, Ma J (corresponding author). Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by MRI: prognostic value and staging categories. Cancer. 2008;113(2):347-354. (IF 5.2)

    10. Tang LL, Mao YP, Liu LZ, Liang SB, Chen Y, Sun Y, Liao XB, Lin AH, Liu MZ, Li L, Ma J (corresponding author). The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer. 2009;115(3):680-688. (IF5.2)

    11. Liu LZ, Liang SB, Li L, Mao YP, Tang LL, Tian L, Liao XB, Cui CY, Lin AH, Ma J(corresponding author).Prognostic Impact of MRI Evidence of Cranial Nerve Involvement in Nasopharyngeal Carcinoma. Cancer. 2009;115(9):1995-2003. (IF5.2)

    12. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL,Guo Y, Lin AH, Liu MZ, Ma J (corresponding author). Progress Report of a Randomized Trial Comparing Long-term Survival and Late Toxicity of Concurrent Chemoradiotherapy with Adjuvant Chemotherapy to Radiotherapy Alone in Stage III–IVB Nasopharyngeal Carcinoma Patients from Endemic Regions of China. Cancer, 2013; 119(12):2230-8 (IF 5.2) 

    13. Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, Zhou GQ, Sun Y, Yue D, Guo R, Mao YP, Li WF, Liu LZ, Tian L, Lin AH, Ma J (corresponding author). Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: Analysis of 1301 patients from an endemic area in China. Cancer. 2014; 120: 68–76. (IF 5.2)

    14. Liu N, Jiang N, Guo R, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J (corresponding author). MiR-451 inhibits cell growth and invasion by targeting MIF and is assocaited with survival in nasopharyngeal carcinoma. Mol Cancer, 2013; 12:123. (IF 5.1) 

    15. Liu X, Liu LZ, Mao YP, Chen L, Tang LL, Zhou GQ, Sun Y, Yue D, Lin AH, Li L, Ma J (corresponding author). Prognostic value of magnetic resonance imaging-detected cranial nerve invasion in nasopharyngeal carcinoma. Br J Cancer. 2014; 110(6): 1465-1471. (IF 5.1) 

    16. Mao YP, Zhou GQ, Liu LZ, Guo R, Sun Y, Li L, Lin AH, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Ma J(corresponding author). Comparison of Radiological and Clinical Features of Temporal Lobe Necrosis in Nasopharyngeal Carcinoma Patients Treated with 2D Radiotherapy or Intensity Modulated Radiotherapy. British Journal of Cancer. 2014. 110(11): 2633-2639. (IF5.1)

    17. Liu N, He QM, Chen JW, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J(corresponding author). Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 2014; 13: 111. (IF 5.1)

    18. Ma J(first author, corresponding author), Mai HQ, Hong MH, Cui NJ, Lu TX, Lu LX, Mo HY, Min HQ. Is the 1997 UICC/AJCC Staging System for Nasopharyngeal Carcinoma Prognostically Useful for Chinese Patient Population? Int J Radiation Oncology Biol Phys. 2001; 50 (5): 1181-1189.(IF 4.5) 

     19. Liu MZ, Tang LL, Zong JF, Huang Y, Sun Y, Mao YP, Liu LZ, Lin AH, Ma J (corresponding author). Evaluation of Sixth Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement. Int J Radiat Oncol Biol Phys. 2008;70(4):1115-1123. (IF 4.5)

    20. Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Guo Y, Lin AH, Zeng XF, Ma J (corresponding author). Preliminary Results of a Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy versus Radiotherapy Alone in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma in Endemic Regions of China. Int J Radiat Oncol Biol Phys. 2008;71(5):1356-1364. (IF 4.5)

    21. Liao XB,MaoYP, LIU MZ,Tang LL,Sun Y,Wang Y, Lin AH, Cui CY, Li L,Ma J(corresponding author) . How does of Magnetic Resonance Imaging Influence on the 6th Edition of the AJCC Staging System for Nasopharyngeal Carcinoma Compared to Computed Tomography? Int J Radiat Oncol Biol Phys. 2008;72(5):1368-1377. ( IF 4.5)

    22. Mao YP, Xie FY, Liu LZ, Chen Y, Sun Y, Tang LL, Tian L, Lin AH, Liu MZ, Li L, Ma J (corresponding author). Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5): 1326-1334.(IF 4.5)

    23. Liang SB, Sun Y, Liu LZ, Mao YP, Tang LL, Chen Y, Tian L, Lin AH, Liu MZ, Li L, Ma J (corresponding author). Extension of Local Disease in Nasopharyngeal Carcinoma as Detected by Magnetic Resonance Imaging: Improvement of Clinical Target Volume Delineation. Int J Radiat Oncol Biol Phys.2009;75(3): 742-750. (IF 4.5)

    24. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J(corresponding author). How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661-8 ( IF 4.5)

    25. Zhou GQ, Mao YP, Chen L, Li WeF, Liu LZ, Sun Y, Chen Y, Tian L, Lin AH, Li L, Ma J (corresponding author). The Prognostic Value of Prevertebral Space Involvement in Nasopharyngeal Carcinoma based on Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(3):1090-7 (IF 4.5)

    26. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, Liu LZ, Li L, Lin AH, Ma J (corresponding author). Baseline Serum Lactate Dehydrogenase Levels for Patients Treated With Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Predictor of Poor Prognosis and Subsequent Liver Metastasis. Int J Radiat Oncol Biol Phys. 2012;82(3): e359-e365 (IF 4.5)

    27. Chen L, Liu LZ, Chen M, Li WF, Yin WJ, Lin AH, Sun Y, Li L, Ma J (corresponding author). Prognostic value of subclassification using MRI in the T4 classification nasopharyngeal carcinoma intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys. 2012;84(1): 196-202 (IF 4.5)

    28. Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J (corresponding author). The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol, 2012; 104(3):331-337 (IF 4.5)

    29. Guo R, Sun Y, Yu XL, Yin WJ, Li WF, Chen YY, Mao YP, Liu LZ, Li L, Lin AH, Ma J (corresponding author). Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol, 2012; 104(3):294-299 (IF 4.5)

    30. Li WF, Sun Y, Mao YP, Chen L, Chen YY, Chen M, Liu LZ, Lin AH, Li L, Ma J (corresponding author). Proposed lymph node staging system using the International Consensus Guidelines for lymph node levels is predictive for nasopharyngeal carcinoma patients from endemic areas treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys, 2013;86(2):249-56 ( IF 4.5) 

    31. Tang LL, Sun Y, Mao YP, Chen Y, Li WF, Chen L, Liu LZ, Lin AH, Li L, Ma J (corresponding author). Prognostic Value of Parapharyngeal Extension in Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy.Radiother Oncol. 2014;110(3):404-8 (IF 4.5) 

    32. Sun Y, Yu XL, Luo W, Lee AWM, Wee JTS, Lee N, Zhou GQ, Tang LL, Tao CJ, Guo R, Mao YP, Zhang R, Guo Y, Ma J (corresponding author). Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol. 2013 (IF 4.5) 

    33. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W, Ma J (corresponding author). MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett, 2013; 329(2):181-188 (IF 4.2)

    34. Cheng YK, Liu LZ,Jiang N, Yue D, Tang LL,Zhang F, Lin L, Liu X, Chen L,Ma J (corresponding author). MRI-detected skull-base invasion: prognostic value and therapeutic implication in nasopharyngeal carcinoma intensity-modulated radiotherapy treatment. Strahlenther Onkol.2014 Apr 25. [Epub ahead of print] (IF 4.2)

    35. Yang S, Wu J, Zuo Y, Tan L, Jia H, Yan H, Zhu X, Zeng M, Ma J(joint corresponding author), Huang WL. ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma. Curr Cancer Drug Targets. 2010;10(6):611-622. (IF 4.0) 

    36. Zhou GQ, Yu XL, Chen M, Guo R, Lei Y, Sun Y, Mao YP, Liu LZ, Li L, Lin AH, Ma J (corresponding author). Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy. Plos One. 2013; 8(7): e67488 (IF 3.7)

    37. Sun Y, Guo R, Yin WJ, Tang LL, Yu XL, Chen M, Qi ZY, Liu MZ, Ma J (corresponding author). Which T category of nasopharyngeal carcinoma may compared with step and shoot intensity modulated radiation therapy. PLoS One. 2013, 8(9): e75304. (IF 3.7)

    38. Jiang W, Li YQ, Liu N, Sun Y, He QM, Jiang N, Xu YF, Chen L, Ma J (corresponding author). 5-Azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in vitro and in vivo possibly by altering DNA methylation.PLoS One. 2014, 9(4): e93273. (IF 3.7) 

    39. Du XJ, Tang LL,Mao YP, Sun Y, Zeng MSH, Kang TB, Jia WH, Lin AH, Ma J (corresponding author). The Pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One. 2014, 9(4): e94437. (IF 3.7)

    40. Li WF, Liu N, Cu RX, He QM, Chen M, Jiang N, Sun Y, Xie D, Zeng J, Liu LZ, Ma J (corresponding author). Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. J Transl Med. 2012; 10(1):78 (IF 3.5)

    41. Sun Y, Tang LL, Chen L, Li WF, Mao YP, Liu LZ, Lin AH, Li L, Ma J (corresponding author). Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventhedition of the AJCC staging system. BMC Cancer, 2012;12:68 (IF:3.3)

    42. Cui RX, Liu N, He QM, Li WF, Huang BJ, Sun Y, Tang LL, Chen M, Jiang N, Chen L, Yun JP, Zeng J, Guo Y, Wang HY , Ma J (corresponding author). Low BRMS1 Expression Promotes Nasopharyngeal Carcinoma Metastasis and Is Associated with Poor Survival of the Patients. BMC Cancer, 2012;12:376 (IF 3.3) 

    43. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, Li L, Lin AH, Ma J (corresponding author). Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer. 2013, 13: 397. (IF 3.3)

    44. Chen L, Liu LZ, Mao YP, Tang LL, Sun Y, Chen Y, Lin AH, Li L, Ma J (corresponding author). Grading of magnetic resonance imaging-detected skull-base invasion in nasopharyngeal carcinoma and its prognostic value. Head Neck. 2011;33(9):1309-1314. (IF 2.8)

    45. Chen M, Tang LL, Sun Y, Mao YP, Li WF, Guo R, Liu LZ, Li L, Lin AH, Ma J (corresponding author). Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy. Head Neck, 2014; 36(4): 468-473. (IF 2.8) 

    46. Jiang N, Liu N, Yang F, Zhou QM, Cui RX, Jiang W, He QM, Li WF, Guo Y, Zeng J, Yun JP, Chen XC, Zhou BP, Sun Y, Wang HY, Chen ZG, Ma J(corresponding author). Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. Oncol Rep. 2014. (Accepted, IF 2.3)

    47. Liu N, Cui RX, He QM, Huang BJ, Sun Y, Xie D, Zeng J, Wang HY, Ma J (corresponding author). Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma. Med Oncol, 2013;30(1):360-368 (IF 2.1)

    48. Yin WJ, Sun Y, Chi F, Fang JL, Guo R, Yu XL, Mao YP, Qi ZY, Guo Y, Liu MZ, Ma J (corresponding author). Evaluation of inter-fraction and intra-fraction errors during volumetric modulated arc therapy in nasopharyngeal carcinoma patients. Radiat Oncol, 2013;8:78 (IF 2.1)

     

    Last Updated on: August 2014

    Xia Yunfei
    Title Professor, Chief Physician, Doctoral Advisor and Director of Department of Radiation Oncology
    Profile
    Prof. Xia Yunfei has been working at Sun Yat-sen University Cancer Center since 1987, and currently serves as Deputy Director of Department of Radiation Oncology. As well as being a professor, he is a chief physician and doctoral advisor. He specializes in clinical work and radiobiology research of oncology radiotherapy, specifically radiotherapy and research of nasopharynx carcinoma, nervous system tumors and lymphoma.
    Email xiajch@sysucc.org.cn
    Phone
    Research Interest(s)

    Radiobiological behavior of malignant tumors

     

    Basic Research:

    The research priority is nasopharynx carcinoma, carried out from three aspects: free radical, photobiology and molecular biology. The research focuses on both spectroscopic techniques of detecting radiosensitivity of nasopharynx carcinoma and molecular mechanism of radioresistance of nasopharynx carcinoma, involving transgene radiosensitization for radioresistant nasopharynx carcinoma.

     

    Clinical Research:

    Based on summary of therapeutic effects of radiotherapy of 1302 cases in the Hospital, as well as such of large-scale cases reported in Shanghai, Fujian, Hunan, Beijing, Hong Kong and abroad, the research puts forwards that nasopharynx carcinoma can be categorized into 4 types regarding its clinical biological behaviors, i.e., lowly metastatic radiosensitive, cancer, lowly metastatic radioresistant cancer, highly metastatic radiosensitive cancer and highly metastatic radioresistant cancer. In accordance with the size of tumor before treatment and tumor regression after radiotherapy, adjuvant radiotherapy with doses of radiation was adopted for stage I and stage II diffuse large B-cell lymphoma. Based on summary of therapeutic effects of adjuvant radiotherapy for 164 cases of glioma of the Hospital, the research put forward the measure of improving biological target volume of adjuvant radiotherapy for glioma to increase the local control rates of stage I and stage II glioma so as to improve the quality of stage III and stage IV glioma.

    Education 1980-1985: Undergraduate, Radiation Medicine, former Suzhou Medical School
    1991-1994: Master's degree student, Sun Yat-sen University Cancer Center
    1999: Visiting scholar, MD Anderson Cancer Center, U.S.
    Publications

    First Author

    1. Comparison on Electron Spin Resonance Power Saturation Characteristics
      between Patients with Nasopharyngeal Carcinoma and Healthy People. International Journal of Modern Cancer Therapy. 1999, 2(1):73-75
    2. Photoacoustic Absorption Characteristics of SUNE-1, CNE-2, and CNE-1 Human Nasopharyngeal Carcinoma Cell Lines Measured Using Photoacoustic Techniques.Cell Biology International 2001, 25(10):1068


    Second Author

    1. The nude mice experiment and clinical study of enhancing radiotherapy effect of hematoporphyrin derivatives on human nasopharyngeal carcinoma.Radiotherapy and Oncology. Vol, 43(Suppl.2): 595
    2. Relationship between radiosensitivity of nasopharyngeal carcinoma cell lines and expression ofKu70, Ku80.Cell Biology International.2004, 28(8-9) ISSN 1065-6995
    3. The effect of DNA-PK antisene oligodeoxynuliotide on the radiosensitivity of nasopharyngeal carcinoma cell with different p53 function status.Cell Biology International.2004, 28(8-9) ISSN 1065-6995
    4. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cell lines with normal p53 function.Cell Biology International.2004, 28(8-9) ISSN 1065-6995
    5. The radiobiological characteristics of the nasopharyngeal carcinoma cell lines with different p53 function status.Cell Biology International.2004, 28(8-9) ISSN 1065-6995
    Liu Mengzhong
    Title Professor
    Profile

    Dr. Liu Mengzhong is a chief physician, professor and doctoral advisor. He graduated from the Department of Clinical Medicine at former Sun Yat-sen University of Medical Sciences (undergraduate program) in 1983 and was awarded a master's degree in Clinical Oncology by former Sun Yat-sen University of Medical Sciences in 1988. Currently he serves as Chief for Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Associate Chief for Oncology Teaching and Research Office of Sun Yat-sen University, and Chief for Radiation Oncology Teaching and Research Office of Sun Yat-sen University. He is also a member of the Chinese Society of Radiation Oncology of Chinese Medical Association, Chairman of Radiation Oncology Branch of Guangdong Medical Association, Chief for Guangdong Radiation Therapy Quality Control Center, and Deputy Chairman of Esophagus Cancer Specialized Committee of Guangdong Anti-cancer Association. Medical Specialties: rich clinical experience in combination therapy of radiation therapy and chemotherapy for thoracoabdominal tumors, nasopharynx carcinoma and prostate tumors.

    Email liumzh@sysucc.org.cn
    Phone 8620-87343649
    Research Interest(s)

    In recent years, he has been mainly engaged in research of thoracoabdominal radiation therapy. He has carried out multi-centric clinical trial in esophagus cancer pre-operation chemoradiotherapy, which has made great progress. He has explored in concurrent chemoradiotherapy schemes and some of his papers in this field have been adopted by NCCN Guidelines. He has reached the leading level in China in thoracoabdominal advanced radiation therapy technologies (4D-CT\IGRT). He has undertaken several projects at national, provincial and ministerial levels. He has published about 70 papers as the lead author or corresponding author, over 20 of which have been included in SCI journals.

    Education
    Publications

    1. Xi M, Zhang L, Liu MZ (corresponding author), et al. Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLoS ONE. 2013; 8(5): e63864.2. Xi M, Zhang L, Liu MZ (corresponding author), et al. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162.3. Xi M, Liu SL, Liu MZ (corresponding author), et al. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013;8(12):e845864. Zhao L, He LR, Xi M, Liu MZ (corresponding author) et al. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3 . J Transl Med. 2012 Dec 11;10(1):249.5. Zhao L, Li QQ, Zhang R, Xi M, Liu MZ (corresponding author) et al. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour Biol. 2012 Aug;33(4):1115-23.6. Zhao L, He LR, Zhang R, Liu MZ (corresponding author) et al. Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2012 Dec;29(4):2669-76.7. Zhang L, Xi M, Deng XW, Liu MZ (corresponding author) et al. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012 Sep;53(5):769-76.8. Li Q, Hu Y, Xi M, Liu MZ (corresponding author) et al. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent mannerBMC Cancer. 2012 Oct 22;12:4859. Xi M, Zhang L, Liu MZ (corresponding author), Deng XW et al., Dosimertic Analysis of Respiratory-Gated Radiotherapy For Hepatocellular Carcinoma Medical Dosimetry. 2011;36(2):213-21810. Xi M, Liu MZ (corresponding author), Deng XW, et al. Radiation-Induced Sarcoma in Patients with Nasopharyngeal Carcinoma: A Single-Institution Study. Cancer. 2010; 116(23): 5479-5486. 11. He LR, Liu MZ (corresponding author), Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010; 127: 138-147.12. Xi M, Zhang L, Liu MZ (corresponding author), et al. Dosimetric Analysis of Respiratory Gated Radiotherapy for Hepatocellular Carcinoma. Med Dosim. 2010; in press. 13. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma. Dis Esophagus. 2010; 23: 253-259.14. Feng Z, Xu S, Liu MZ (all as lead authors), et al. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 2010; 297(2): 190-197.15. He LR, Liu MZ (corresponding author), Li BK, et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009 Dec 22; 9: 461. 16. He LR, Liu MZ (corresponding author), Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(9): 1591-1596.17. Xi M, Liu MZ (corresponding author), Zhang L, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259. 18. He LR, Liu MZ (corresponding author), Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(12): 2354-2360. 19. Chen Y, Liu MZ (both as lead authors), Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008; 71(5): 1356-1364. 20. Liu MZ, Tang LL, Zong JF, et al. Evaluation of Sixth Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement. Int J Radiat Oncol Biol Phys. 2008; 70(4): 1115-1123. 21. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008; 129(5): 728-734. 22. Xi M, Liu MZ (corresponding author), Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol, 2007, 84(3): 272-278.23. Xie CF, Liu MZ (corresponding author), Xi M. A comparative study on radiology and pathology target volume in hepatocellular carcinoma. Chinese Journal of Clinical Oncology. 2010; 37(21)24. Xi M, Liu MZ (corresponding author), Li .QQ, et al. Analysis of abdominal organ motion using four-dimensional CT. Chinese Journal of Cancer. 2009; 28(9): 989-993.25. Xi M, Liu MZ (corresponding author), Deng XW, et al. Definition of internal target volume and domestric study for hepatocellular carcinoma using four-dimensional CT. Chinese Journal of Radiation Oncology. 2009; 18(6): 435-439.26. Yang J, Liu MZ (corresponding author), Cai L, et al. Phase II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2008, 27(6): 622-62627. Xi M, Liu MZ (corresponding author), Deng XW, et al. Internal target volume definition using four-dimensional CT and dosimetric evaluation for hepatocellular carcinoma. Chinese Journal of Cancer, 2007, 26(1): 1-8.28. Liu MZ, He LR, Lu TX, et al. Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma. Chinese Journal of Oncology. 2006, 28(12): 932-937.29. Wang XS, Liu MZ (corresponding author), Zhang CQ, et al. Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients -- a report of 43 cases. Chinese Journal of Cancer, 2006, 25(11): 1428-1432.30. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Chinese Journal of Cancer, 2006, 25(6): 723-72731. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(6): 731-734.32. Cai L, Liu MZ (corresponding author), et al., Rong TH. Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2005, 24(5): 582-586.33. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(4): 498-501.34. Liu MZ, Wang XS, Cai L, et al. External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer. Chinese Journal of Cancer, 2005, 24(1): 82-86.Compilation of Books:1. Practical Radiation Oncology, Sun Yat-sen University Press, 1st edition, 12/2005 Associate Editor.2. Clinical Oncology, Science Press, 2nd edition, 09/2005 Editorial Board Member.3. Minimal Invasive Treatment and Multidisciplinary Compositive Treatment of Liver Cancer, Military Medical Science Press, 1st edition, 10/2003 Editorial Board Member.4. Radiation Therapy Handbook for Common Malignant Tumors, Peking University Medical Press, 1st edition, 01/2010 Chief Editor.Performance in projects at national, provincial and ministerial levels1. National Key Technologies R & D Program of China during the 9th Five-Year Plan Period: Clinical work of multidisciplinary compositive treatment for primary liver cancer (subtitle: clinical work of external radiation and combined TACE treatment for residual liver cancer). 01/1997 - 12/1999, RMB 50,000, completed.2. Science and Technology Program of Guangzhou, China (2001-Z-043-01-7): Clinical work of a new type of radiosensitizer (CM-Na) in treatment for nasopharynx carcinoma and primary liver cancer. 01/2002 - 12/2004, RMB 50,000, completed.3. Project of Guangdong Provincial Department of Science and Technology (2004B30301016): CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. 01/2005 - 12/2007, RMB 80,000, completed.4. Project of Guangdong Provincial Department of Science and Technology (2006B36002005): A study on 4D-CT respiratory gating radiation therapy for liver cancer. 01/2007 - 12/2009, RMB 50,000, completed.5. Project of Guangdong Provincial Department of Science and Technology (2009B080701036): A study on the clinical application of image guided radiation therapy to thoracoabdominal tumor. 01/2010 - 12/2012, RMB 150,000, completed.6. 2007 First person in charge of key specialties of Medicine in Guangdong (funded by Health Department of Guangdong Province, RMB 100,000 per year). 7. 2012 Clinical application of self-adaption radiation therapy (Project of Guangdong Provincial Department of Science and Technology 2012B031800287, RMB 100,000) 2013-2015 First person in charge.2012 A study on the influence of EGFR signal channel regulating IGFBP3 expression in esophagus cancer chemoradiotherapy sensibility and its mechanism (National Natural Science Foundation of China 81272487, RMB 700,000) 2013-2016 First person in charge

     

    Last Updated on: July 2014
    Sun Ying
    Title Chief physician, Associate Chief for Department of Radiation Oncology
    Profile
    Dr. Sun Ying MD, PhD, is an advisor of master's degree student and winner of the Youth Talent Training Program of Sun Yat-sen University Cancer Center (2009). She received the Doctoral degree in Imaging and Nuclear Medicine from the Second Affiliated Hospital, Sun Yat-sen University in 2002. She has been working in Radiation Oncology at Sun Yat-sen University Cancer Center since then, focusing both on clinical and scientific research work. She specializes in clinical diagnosis, radiation therapy and combination therapy of head and neck cancer, especially nasopharynx carcinoma. She has published 11 SCI papers as the lead author or corresponding author on mainstream journals including Int J Radiat Oncol Biol Phys (IF: 4.3), Radiother Oncol (IF: 4.5), Plos One (IF: 3.7), BMC Cancer (IF: 3.3), etc.
    Email sunying@sysucc.org.cn
    Phone 020-87343032
    Research Interest(s)
    1. General program of National Natural Science Foundation of China: Study on individualized CTV of nasopharynx carcinoma based on imaging and molecular biology (2011-2013, the first leader)2. General program of National Natural Science Foundation of China: Study on mechanism of regulating and controlling E-cadherin expression by promoter methylation of candidate tumor suppressor gene KRAB-ZNF671 in the process of metastasis of nasopharynx carcinoma (2014--2017, the first leader)3. Program of Guangdong Provincial Department of Science and Technology: Prospective study on IMRT individualized CTV of nasopharynx carcinoma based on principles of MRI (2010--2012, the first leader)4. Program of Guangdong Natural Science Foundation: Studies on significance and function of nasopharynx carcinoma prognosis (2011--2013, the first leader)5. Program of Guangdong Natural Science Foundation: Studies on the biological function and clinical significance of candidate tumor suppressor gene KRAB-ZNF671 in nasopharynx carcinoma (2013--2015, the first leader)6. Talent Program of Sun Yat-sen University Cancer Center (2009--2013, the first leader)7. Sun Yat-Sen University Clinical Research 5010 Program: Study on individualized CTV of nasopharynx carcinoma based on risk map of lesions caused (2013--2022, the first leader)8. Key Clinical Program of the Ministry of Health: Perspective studies on nasopharynx carcinoma prognosis model and TPF induction chemotherapy based on IMRT (2010--2013, the second leader)
    Education
    09/1992-06/1997 Bachelor's Degree in Medical Imaging, Harbin Medical University09/1997-06/2002 Doctoral Degree in Imaging and Nuclear Medicine, The Second Affiliated Hospital, Sun Yat-sen University
    Publications
    1. Sun Y, Yu XL, Luo W, Lee AWM, Wee JTS, Lee N, Zhou GQ, Tang LL, Tao CJ, Guo R, Mao YP, Zhang R, Guo Y, Ma J. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol. 2014 Mar;110(3):390-7 (IF 4.5) 2. Sun Y, Guo R, Yin WJ, Tang LL, Yu XL, Chen M, Qi ZY, Liu MZ, Ma J. Which T category of nasopharyngeal carcinoma may benefit most from volumetric modulated arc therapy compared with step and shoot intensity modulated radiation therapy. Plos One. 2013;8(9):e75304 (IF 3.7)3. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, Li L, Lin AH, Ma J. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer. 2013;13:397 (IF 3.3)4. Sun Y, Tang LL, Chen L, Li WF, Mao YP, Liu LZ, Lin AH, Li L, Ma J. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventhedition of the AJCC staging system. BMC Cancer, 2012;12:68 (IF:3.3)5. Tang LL, Sun Y(Co-first authors), Mao YP, Chen Y, Li WF, Chen L, Liu LZ, Lin AH, Li L, Ma J. Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiother Oncol. 2013 (IF 4.5) Article in press6. Guo R, Sun Y (Co-first authors), Yu XL, Tang LL, Yin WJ, Qi ZY, Ma J. Is primary tumor volume still a prognostic factor in Intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol, 2012; 104(3):294-299 (IF 4.5) 7. Chen Y, Sun Y (Co-first authors), Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress Report of a Randomized Trial Comparing Long-term Survival and Late Toxicity of Concurrent Chemoradiotherapy with Adjuvant Chemotherapy to Radiotherapy Alone in Stage III–IVB Nasopharyngeal Carcinoma Patients from Endemic Regions of China. Cancer, 2013; 119(12):2230-8 (IF 5.2)8. Li WF, Sun Y (Co-first authors), Mao YP, Chen L, Chen YY, Chen M, Liu LZ, Lin AH, Li L, Ma J. A proposed N staging system using the International Consensus Guidelines for lymph node levels is predictive for nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy in endemic areas. Int J Radiat Oncol Biol Phys, 2013;86(2):249-56 (IF:4.5)9. Liang SB, Sun Y (Co-first authors), Liu LZ, Mao YP, Tang LL, Chen Y, Tian L, Lin AH, Liu MZ, Li L, Ma J. Extension of Local Disease in Nasopharyngeal Carcinoma as Detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys, 2009;75(3):742-750 (IF:4.5)10. Yin WJ, Sun Y (Co-first authors), Chi F, Fang JL, Guo R, Yu XL, Mao YP, Qi ZY, Guo Y, Liu MZ, Ma J. Evaluation of inter-fraction and intra-fraction errors during volumetric modulated arc therapy in nasopharyngeal carcinoma patients. Radiat Oncol, 2013;8:78 (IF 2.1)11. Liu N, Cui RX, Sun Y (Co-first authors), Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, Cho WC, Liu LZ, Li L, Ma J. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngealcarcinoma. Int J Cancer, 2014; 134: 1359-1368. (IF 6.2)12. Tao CJ, Liu X, Tang LL, MaoYP, Chen L, Li WF, Yu XL, Liu LZ, Zhang R, Lin AH, Ma J, Sun Y (Correspondence author).Chin J C Prognostic scoring system for locoregional control among nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer, 2013; 32(9): 494-50113. Tao CJ, Liu X, Tang LL, MaoYP, Chen L, Li WF, Yu XL, Liu LZ, Zhang R, Lin AH, Ma J, Sun Y (Correspondence author). Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chin J Cancer, 2013; 32(10):525-53214. Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, Chen L, Zhou GQ, Li L, Ma J(corresponding author).Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer, 2012; 31(12):579-58715. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W, Ma J. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 2013; 329(2):181-188 (IF 4.2)16. Mao YP, Liang SB, Liu LZ, Chen Y, Sun Y, Tang LL, Tian L, Lin AH, Liu MZ, Li L, Ma J. The N-staging System in Nasopharyngeal Carcinoma with RTOG Guidelines for Lymph Node Levels Based on Magnetic Resonance Imaging. Clin Cancer Res.2008;14(22):7497-7503.( IF 7.8)17. Tang LL, Li L, Mao YP, Liu LZ, Liang SB, Chen Y, Sun Y, Liao XB, Tian L, Lin AH, Liu MZ, Ma J. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by MRI: prognostic value and staging categories. Cancer. 2008;113(2):347-354. (IF 5.2)18. Liu MZ, Tang LL, Zong JF, Huang Y, Sun Y, Mao YP, Liu LZ, Lin AH, Ma J . Evaluation of Sixth Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement. Int J Radiat Oncol Biol Phys. 2008;70(4):1115-1123. (IF 4.5)19. Liao XB, Mao YP, Liu LZ, Tang LL, Sun Y, Wang Y, Lin AH, Cui CY, Ma J. How does of Magnetic Resonance Imaging Influence on the 6th Edition of the AJCC Staging System for Nasopharyngeal Carcinoma Compared to Computed Tomography? Int J Radiat Oncol Biol Phys. 2008;72(5):1368-1377. ( IF 4.5)20. Mao YP, Xie FY, Liu LZ, Chen Y, Sun Y, Tang LL, Tian L, Lin AH, Liu MZ, Li L, Ma J. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5): 1326-1334.(IF 4.5)21. Tang LL, Mao YP, Liu LZ, Liang SB, Chen Y, Sun Y, Liao XB, Lin AH, Liu MZ, Li L, Ma J. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer. 2009;115(3):680-688. (IF5.2)22. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J. The Prognostic Value and Staging Categories of Anatomical Masticator Space Involvement in Nasopharyngeal Carcinoma: A study of 924 cases based on magnetic resonance imaging. Radiology. 2010;257(1):151-157. (IF 6.3) 23. Chen L, Liu LZ, Mao YP, Tang LL, Sun Y, Chen Y, Lin AH, Li L, Ma J. Grading of magnetic resonance imaging-detected skull-base invasion in nasopharyngeal carcinoma and its prognostic value. Head Neck. 2011;33(9):1309-1314. (IF 2.8)24. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661-8 ( IF 4.5)25. Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J. The seventh edition of the UICC/AJCC staging system for nasopharyngeal4 carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiotherapy and Oncology. 2012; 104(3):331-337 (IF 4.5)26. Zhou GQ, Mao YP, Chen L, Li WeF, Liu LZ, Sun Y, Chen Y, Tian L, Lin AH, Li L, Ma J. The Prognostic Value of Prevertebral Space Involvement in Nasopharyngeal Carcinoma based on Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(3):1090-7 (IF 4.5)27. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, Liu LZ, Li L, Lin AH, Ma J. Baseline Serum Lactate Dehydrogenase Levels for Patients Treated With Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Predictor of Poor Prognosis and Subsequent Liver Metastasis Int J Radiat Oncol Biol Phys. 2012;82(3): e359-e365 (IF 4.5) 28. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163-171. (IF 25.1)29. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho William, Yun JP, Zeng J, Liu LZ, Guo Y, Wang HY, Ma J. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633-641. (IF 25.1) 30. Chen L, Liu LZ, Chen M, Li WF, Yin WJ, Lin AH, Sun Y, Li L, Ma J. Prognostic value of subclassification using MRI in the T4 classification nasopharyngeal carcinoma intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys. 2012;84(1): 196-202 (IF 4.5)31. Li WF, Liu N, Cu RX, He QM, Chen M, Jiang N, Sun Y, Xie D, Zeng J, Liu LZ, Ma J. Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. Journal of Translational Medicine. 2012; 10(1):78 (IF 3.5)32. Cui RX, Liu N, He QM, Li WF, Huang BJ, Sun Y, Tang LL, Chen M, Jiang N, Chen L, Yun JP, Zeng J, Guo Y, Wang HY , Ma J. Low BRMS1 Expression Promotes Nasopharyngeal Carcinoma Metastasis and Is Associated with Poor Survival of the Patients. BMC Cancer. 2012;12:376 (IF 3.3)33. Sun Y, Mao YP, Ma J, Huang Y, Tang, LL, Wang Y, Liu LZ, Lu TX. Influence of magnetic resonance imaging on the staging system of nasopharynx carcinoma. Chinese Journal of Cancer 2007; 26(2):158-163.34. Sun Y, Ma J, Lu TX, Wang Y, Huang Y, Tang, LL. Regulation for distribution of metastatic cervical lymph nodes of 512 cases of nasopharynx carcinoma. Chinese Journal of Cancer 2004; 23(11S):1523-1527.35. Sun Y, Ma J, Huang Y, Tang LL, Li L, Wang Y, Lu TX. The study of the comparison of CT and MRI in nasopharynx carcinoma. Chinese Journal of Clinical Oncology 2005;32(14):788-791.36. Sun Y, Shen J, Ma J, Lu TX, Liang BL, Chen JY, Huang Y, Ding ZX. Comparison of CT and MRI in the detection of primary tumor extension of nasopharynx carcinoma: analysis of 283 cases. Chinese Journal of Medical Imaging Technology 2005;21(11):1693-1696.37. Mao YP, Hong MH, Sun Y, Liang SB, Li L, Liu LZ, Tang LL, Cao SM, Lin AH, Lu TX, Liu MZ, Ma J. Clinical staging of nasopharynx carcinoma based on MRI: suggestions for improving the Chinese '92 staging system. Chinese Journal of Cancer 2007;26(10): 1099-l106.38. Yu, XL, Zhang GS, Chen M, Guo Y, Sun Y (Corresponding author). Suggestion of a contouring method of temporal lobe in intensity-modulated radiotherapy (IMRT) for nasopharynx carcinoma. Journal of Sun Yat-sen University (Medical Sciences) 2013;34(4):627-637.
     
    Last Updated on: August 2014
    Gao Yuan-Hong
    Title Chief Physician, Professor and Deputy Director of Radiation Oncology Department
    Profile

    Dr. Yuan-Hong Gao is a professor of radiation oncology of Sun Yat-sen University Cancer Center. Dr. Gao obtained his Bachelor in Medicine (equivalent to MD in the US) at Jiangxi Medical College and a PhD at Peking Union Medical College, P. R. China in 1991 and 2002, respectively. His postdoctoral training at Baylor College of Medicine provided him with great opportunities to explore the fields of molecular target therapy and radio sensitivity from 2006 to 2008.

    He joined the Department of Radiation Oncology of the Sun Yat-sen University Cancer Center (SYSUCC) as an attending physician in July 2002, he then became a vice-professor in 2006, and finally a Professor in 2013. Dr. Gao has been well trained both in the fields of clinical treatment and cancer research, especially for the fields colorectal cancer, nasopharyngeal carcinoma and pediatric tumors. Dr. Gao has published more than 50 research papers.

    Email gaoyh@sysucc.org.cn
    Phone 020-87343491
    Research Interest(s) Clinical and basic research on colorectal cancer
    Education

    Sep. 2006-Jun. 2008 Baylor College of Medicine Post-Doc 

    Sep. 1997-Jun. 2002 Peking Union Medical College Ph.D. 

    Sep. 1986-Jun. 1991 Jiangxi Medical College MD.

    Publications

    1) Yuan-Hong Gao, Jun-Zhong Lin, Xin An, Jie-Lin Luo,Mu-Yan Cai, Pei-Qiang Cai, Ling-Heng Kong, Guo-Chen Liu, Jing-Hua Tang, Gong Chen, Zhi-Zhong Pan, Pei-Rong Ding.Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently with, and Following Radiotherapy in Locally Advanced Rectal Cancer:A Prospective Phase II Trial. Int J Radiat Oncol Biol Phys. 2014.(Article accepted for publication: 14-JUL-2014)(IF:4.176)

    2) Kai-Yun You, Rong Huang,Yuanhong Gao(correspondence).Adjuvant chemotherapy for rectal cancer. Lancet Oncol.2014, 15(6): e194. (correspondence)(IF 25.117)

    3) Kai-Yun You,Yuanhong Gao(correspondence). Can tumor location predict effectiveness of Bevacizumab conducted in the first-line setting for metastatic colorectal cancer. Ann Oncol. 2014, 25(2):545-546. (correspondence)(IF:7.384)

    4) Kai-Yun You,Yuanhong Gao(correspondence). Can Quantified pathologic response assessed as residual tumor burden be a promising stage system for rectal cancer treated with chemoradiation followed by surgery? Cancer. 2014 120(8):1281-2. (correspondence)(IF:5.201)

    5) Gao YH, Zhang X, An X, Cai MY, Zeng ZF, Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ,Ding PR,et al. Oxaliplatin and capecitabine administered concomitant to neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlentherapie und Onkologie. 2014, 190(2): 158-164. IF: 4.163 )

    6) Kai-yun You, Rong Huang, Pei-rong Ding, Bo Qiu, Guan-qun Zhou, Hui Chang, Wei-wei Xiao, Zhi-fan Zeng, Zhi-zhong Pan, Yuan-hong Gao(correspondence). Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis. 2014, 29(4): 529-538 (IF:2.385)

    7) Gao YH, An X, Sun WJ, Cai J, Cai MY, Kong LH, Lin JZ, Liu GC, Tang JH, Wu XJ, Chen G, Pan ZZ, Ding PR. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer . J Surg Oncol. 2014, 109(5):478-82 (IF:2.644)

    8) Hai-Hua Peng, Kai-Yun You, Cheng-Tao Wang, Rong Huang, Hong-Bo Shan, Jian-Hua Zhou, Xiao-Qing Pei, Yuan-Hong Gao(correspondence), Bi-Xiu Wen,Meng-Zhong Liu. Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy . Gastroenterology Report. 2013,1:186-192

    9) Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011. 6: 39-44. (IF: 2.381)Rao B, Gao Y (co-author), Huang J, Gao X, Fu X, Huang M, Yao J, Wang J, Li W, Zhang J, Liu H, Wang L, Wang J.Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011. 26(5): 593-601. (IF: 2.415 )

    10) Ren YF, Gao YH (co-author), Cao XP, Ye WJ, Teh BS.3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma. Radiat Oncol. 2010. 5: 113-116. (IF: 2.381)

    11) Y. Gao, X. Wang, J. Zhu, W. Mai, Y. Huang, D. Floryk, M. Ittmann, T. Thompson, E.B. Butler, B.S. Teh. Combined Perifosine (PI3K/AKT Inhibitor) and Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1): S712-S713.

    12) Rao B, Gao Y, Zhou Q, Xiao P, Xia S, Ma J, Luo J, Xiao T, Le S, Huang M, Wang J. A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model. J Cancer Res Clin Oncol. 2013, 139(6):1015-23. (IF: 3.009)

    13) Pei-Rong Ding, Yuan-Hong Gao, Xin An, Gong Chen, Feng-Hua Wang, Mu-Yan Cai, Zhi-Fan Zeng, Ling-Heng Kong, Jun-Zhong Lin, Xiaojun Wu, Zhen-Hai Lu, Li-Ren Li,De-Sen Wan and Zhi-Zhong Pan. Oxaliplatin and capecitabine initially concomitant to radiotherapy then administered in the resting period in highrisk locally advanced rectal cancer. JCO. 2013. 31(4): 581. (Abstract) (IF: 17.879)

    14) Yu-Feng Ren, Xin-Ping Cao, Jia Xu, Wei-Jun Ye, Yuan-Hong Gao, Bin S Teh and Bi-Xiu Wen. 3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Radiation Oncology. 2013,2013, 8:165

    15) Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX, Gao Y, Mai W, Furge K, Qian CN, Amato R, Butler EB, Teh BT, Teh BS. Radiosensitization by inhibiting STAT1 in renal cell carcinoma.Int J Radiat Oncol Biol Phys. 2009 Jan 1; 73(1): 288-295.

    16) Wu SX, Chua DT, Deng ML, Zhao C, Li FY, Sham JS, Wang HY, Bao Y, Gao YH, Zeng ZF. 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007, 69(3): 761-769. 

    17) Xiao Lin, Deng Wenjing, Huang Rong, Zhou Guanqun, Xiao Weiwei, Chen Li, Qiu Bo, Chang Hui, Gao Yuanhong(correspondence), Liu Mengzhong. Distribution of residual cancer cells in bowel wall and its associated factors in patients with rectal cancer after preoperative VMAT with concurrent chemotherapy. Chinese Journal of Radiation Oncology,2014, 23(3):210-214

    18) Xiao Lin, Huang Rong, You Kaiyun, Chen Li, Chang Hui, Zhou Guanqun, Qiu Bo, Xiao Weiwei, Gao Yuanhong(correspondence), Liu Mengzhong. Study on feasibility of preoperative neoadjuvant chemoradiotherapy based on volumetric modulated arc therapy for locally advanced rectal cancer. Chinese Journal of Radiation Oncology,2014, 23(1): 9-13.

    19) Xiao Lin, Huang Rong, You Kaiyun, Chang Hui, Qiu Bo, Xiao Weiwei, Gao Yuanhong(correspondence), Liu Mengzhong. Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer. Chin J Gastrointest Surg, 2014, 17(3): 219-224 .

    20) Xiao Lin, Gao Yuanhong(correspondence), Liu Mengzhong. Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer. Chin J Gastrointest Surg, 2014, 17(1): 93-97.

    21) PENG Hai-hua, YOU Kai-yun, WANG Cheng-tao, HUANG Rong, CHANG Hui, ZHOU Guan-qun, ZENG Zhi-fan, LIU Meng-zhong, WEN Bi-xiu, GAO Yuan-hong(correspondence). Prognostic effects of pathological stages in patients with locally advanced rectal cancer after neoadjuvant radiochemotherapy plus radical surgery. Chinese Journal of Radiation Oncology,2013, 22(6):439-442.

    22) PENG Hai-hua, YOU Kai-yun, WANG Cheng-tao, HUANG Rong, Shan Hongbo,Zhuo Jianhua,Pei Xiaoqin,WEN Bi-xiu, LIU Meng-zhong, GAO Yuan-hong(correspondence)。Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. .Chin J Gastrointest Surg, 2013, 16(12):1203-1207.

    23) PENG Hai-hua, YOU Kai-yun, GAO Yuan-hong(correspondence), CHEN Li, DU Le-hui, CHEN Lei, ZHOU Guan-qun, ZENG Zhi-fan, WEN Bi-xiu, GAO Yuan-hong Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients achieving pathologically complete response after operation following concurrent three-dimensional conformal radiotherapy and chemotherapy. Chinese Journal of Radiation Oncology. 2013, 22(1): 5-8.

    24) You Kai-yun, Peng Hai-hua, GAO Yuan-hong (correspondence),et al. Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy. Chinese Journal of Oncology. 2013,35(9):707-713

    25) Zheng Xues-ong,Han Ning, Kuang Lu, Huang Guan-gyu, GAO Yuan-hong(correspondence). Typical WAGR Syndrome: A Case Report. Chin J Pediatr, 2013,51(3):237-239.

    26) Ye Xu-juang, GAO Yuan-hong (correspondence), Chen Li, Du Le-Hui, Zhang Guang-shun, Jia Yu-ming, Lei Kai-jian, Liu Meng-zhong. Dosimetric comparison between preoperative five-field intensity modulated radiotherapy and volumetric modulated arc therapy in the treatment of rectum cancer. Chinese Clinical Oncology. 2012. 17(8):717-720.

    27) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. An analysis of the combined treatment model for Wilms’ tumor. Chin J Urol. 2012,33(3):180-184.

    28) WAGN Juan, ZHEN Zi-Jun, LIU Jun-cheng, LIU Zhuo-wei, ZHU Jia, CAI Yue, LING Jia-yu, CHEN Yan, CAI Rui-qing, SUN Xiao-fei, GAO Yuan-hong(correspondence). The value of primary site radiotherapy in stage Ⅳ high-risk neuroblastoma. Chinese Journal of Radiation Oncology. 2012, 21(1): 13-15.

    29) Ye Xu-juang, GAO Yuan-hong (correspondence), LIU Bing-ti, CHEN Li, DU LE-hue, ZENG ZHI-fan, ZHANG Guang-sun, Jia Yu-ming, Lei Kai-jian, Liu Meng-zhong. Dosimetric study of 3D conformal radiotherapy compared with 5F intensity modulated radiotherapy in preoperative rectal cancer. CHIN J CANCER PREV TREAT. 2012,19(1):19-23.

    30) Yang Yong, GAO Yuan-hong(correspondence), Liu Bing-ti, Zhang Yu-jing, Du Lei-hue, Liu Hui, Liu Meng-zhong. A Clinical analysis of 54 cases of esthesioneuroblastoma. Journal of SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES). 2011. 32 (4): 553-556.

    31) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. Clinical analysis of 6 cases of primary small cell carcinoma of the larynx. Chin J Otorhinolaryngol Head Neck Srug,2011, 46(9):758-760.

    32) Yang Yong, GAO Yuan-hong(correspondence),Zhang Yu-jing, Gu Mu-fa, Liu Hui, Hu Wei-han, Wu Shao-xiong, Xia Yun-fei, Liu Meng-zhong. A Clinical analysis of 54 cases of esthesioneuroblastoma. Chinese Journal of Radiation Oncology. 2011. 20(2):94-95. 

    33) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. Clinical analysis of 6 cases of pulmonary blastoma. Cance Research on Prevention and Treatment. 2011.38(10):1214-1216.

     

    Last Updated on: August 2014

    Xie Fangyun
    Title Chief physician, Professor and Advisor of Master's Degree student
    Profile
    Prof. Xie Fangyun was born in 1963. He completed his master's program from the former Sun Yat-sen University of Medical Sciences, and has been engaged in medical treatment, teaching and scientific research at Sun Yat-sen University Cancer Center for more than ten years. In 2011, he was engaged as chief physician at Sun Yat-sen University Cancer Center. He specializes in radiotherapy for head and neck cancer, especially combination therapy for nasopharynx carcinoma.
    Email xiefy@sysucc.org.cn
    Phone
    Research Interest(s)
    He has participated in several major projects funded by National Natural Science Foundation of China and Ministry of Health. He has also published multiple lead journals of oncology such as Annals of Oncology, British Journal of Cancer, Cancer Epidemiology Biomarkers & Prevention, The Journal of Biological Chemistry, Cancer Investigation on staging system, prognosis models, combination therapy and etc. of nasopharynx carcinoma. His research results on the relationship between smoking status and prognosis of nasopharynx carcinoma was considered to be profound discovery by American Association for Cancer Research (AACR), and published as a key report on its website, which at the same time, brought extensive attention of media at home and abroad.
    Education
    1985: Graduated from former Hunan Medical University (currently Xiangya School of Medicine of Central South University)1994: Obtained a master's degree of former Sun Yat-sen University of Medical Sciences
    Publications
    1. OuYang PY, … , Xie FY(通讯作者). Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis .... Ann Oncol. 2013; 24(8): 2136-46. (IF 2012 = 7.384)
    2. OuYang PY, … , Xie FY(通讯作者). Prognostic impact of family history in southern Chinese patients …. Br J Cancer. 2013; 109(3): 788-94. (IF 2012 = 5.082)
    3. OuYang PY, … , Xie FY(通讯作者). Prognostic value of ABO blood group in …. Br J Cancer. 2013;109(9):2462-6. (IF 2012 = 5.082)
    4. OuYang PY, … , Deng W, Xie FY(共同通讯作者). Prognostic impact of cigarette smoking…. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2285-94. (IF 2012 = 4.559)
    5. OuYang PY, … , Deng W, Xie FY(共同通讯作者). Combination of EGFR-TKIs and chemotherapy as first-line therapy …. PloS One. 2013;8(11):e79000. (IF 2012 = 3.730)
    6. OuYang PY, … , Liu MZ, Xie FY(共同通讯作者). Comparison of TNM staging systems for …. Br J Cancer. 2013;109(12):2987-97. (IF 2012 = 5.082)
    7. Wang X, … , Yun JP, Xie FY(通讯作者). Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest. 2012;30(1):79-85. (IF 2012 = 2.24)
    8. Xu HM, … , Xie FY, Kang TB(共同通讯作者). Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer. 2011;30(3):204-12. (IF 2012 = 1.00) 
    9. Lv XB, Xie F(共同第一作者), … , Kang T. Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1. J Biol Chem. 2010;11;285(24):18234-40. (IF 2012 = 4.65)
    Zhang Yujing
    Title Professor, Chief physician, and advisor of master's degree student
    Profile

    Prof. Zhang specializes in clinical work of oncology radiotherapy and combination therapy, and relevant radiation and molecular biological studies, especially radiotherapy and research of gastrointestinal tumors and soft tissue sarcoma such as lymphoma, breast cancer, gastric cancer and pancreatic cancer.

    Work experience

    1995-1999: Served as a physician and attending physician in the Department of Radiotherapy, Cancer Center of Qilu Hospital of Shandong University;

    2002-present: associate chief physician of Radiation Oncology at Sun Yat-sen University Cancer Center;

    2008-2009: Conducted research work at Texas Children's Cancer Center of Baylor College of Medicine;

    2010-2011: Guest doctor and supporting expert for the Department of Breast and Thoracoabdomine at Cancer Hospital of Xinjiang Medical University.

    Email zhangyj@sysucc.org.cn
    Phone
    Research Interest(s)

    Prof. Zhang specializes in clinical work of oncology radiotherapy, especially radiotherapy and combination therapy for lymphoma, breast cancer, gastropancreatic tumor, and soft tissue sarcoma. He has been engaging himself in the clinical and relevant researches of the above-mentioned cancer in renowned cancer centers at home and abroad, accumulating abundant experiences from his 20 years of clinical practices. He conducts in-depth researches of radiotherapy of breast cancer and radiotherapy indications of early breast cancer; masters and has unique insights into diagnosis and treatment of extranodal NK/T-cell lymphoma, nasal type, and primary extranodal lymphoma in locations such as Waldeyer's tonsillar ring, gastrointestine, bone, breast and orbit; takes the lead in adopting new IMRT for radiotherapy and combination therapy for gastric cancer and pancreatic cancer.

     

    He had undertaken doctoral and postdoctoral researches in the field of oncology molecular radiobiology in a renowned cancer laboratory, research interest including radiobiology of high LET ray, regulation and control of radiosensitivity of cancer stem cells, individualized prediction of radiation effects of cancer tissue and normal tissue and etc.

    Education
    1986-1992: Undergraduate of Medicine of English Teaching Class (six-year program), School of Clinical Medicine of former Shandong Medical University
    1992-1995: Master's degree student of general surgery of former Shandong Medical University

    1995-2000: Doctoral student of radiation oncology at Cancer Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College

    2007-2008: Worked and studied at University of Texas MD Anderson Cancer Center
    Publications
    1. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31(3):860.
    2. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ*. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumor Biology. 2014; 35(3): 2141-2149.
    3. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ*. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.  Int J Hematol. 2012; 96(5):617-623.
    4. Iyengar P, Strom EA, Zhang YJ, Whitman GJ, Smith BD, Woodward WA, Yu TK, Buchholz TA.  The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist. 2012; 17(11):1402-1408.
    5. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma.  Neuro Oncol. 2012; 14(5):574-583.
    6. Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO. Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys. 2012; 83(1): 284-291.
    7. Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011; 13(1): 14-27.
    8. Zhang YJ, Oh JL, Whitman GJ, Iyengar P, Yu TK, Tereffe W, Woodward WA, Perkins G, Buchholz TA, Strom EA. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys. 2010; 77(4): 1113-1119.
    9. Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM, Su JM, Perlaky L, Dauser R, Chintagumpala M, Lau CC, Blaney SM, Rao PH, Leung HC, Li XN. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010; 12(6): 580-594.
    10. Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008; 3(8): 858-64.
    Chen Kai
    Title Chief Physician
    Profile
    Dr Chen Kai is professor in the of Department of Radiation Oncology, at Sun Yat-sen University Cancer Center. He obtained his Bachelor in Medicine (equivalent to MD in the US) at Beijing University of Chinese Medicine P.R. China in 1982. In 1989, he received his Master’s degree in Clinical medicine. He has been engaged in the radiation therapy of malignant tumors and comprehensive treatment of cancer since then. In 2001, Dr Chen was promoted to be the Chief Physician. From 2005 to 2009, he was working as the director of the Out-patient department and the Chief Physician of the department of Radiation Oncology. Nowadays, he is the Chief Physician and Attending Professor of the department of Radiotherapy. With extensive expertise and experience in clinical medicine, Dr. Chen is good at treating thoracic malignant tumors (Lung cancer, esophagus cancer, malignant thymoma), nasophyaryngeal carcinoma and head-neck cancers.
    Email chenkai@sysucc.org.cn
    Phone 020 87343545
    Research Interest(s)
    Major research areas include the comprehensive treatment of radiotherapy of Chest tumor (lung cancer, esophagus cancer, malignant thymoma), nasopharyngeal carcinoma、head and neck cancers.
    Education

    1982: obtained the Bachelor in Medicine 

    1983 -- 1986: engaged in medical clinical work 

    1989: received Master’s Degree in Clinical medicine

    Publications
    Wei-Han Hu
    Title Professor
    Profile
    Dr. Wei-Han Hu was born in 1954, and obtained his Bachelors in Medicine (equivalent to MD in the US) at Sun Yat-sen Medical college in 1976. Dr. Hu is a professor in the Department of Radiation Oncology, at Sun Yat-sen University Cancer Center. Prof. Hu is also appointed as Chief Physician, Master Supervisor, and tutor of long-term medical education. Prof. Hu has been engaged in clinical radiotherapy, radiobiological research, and education for 40 years. He is good at radiotherapy for head and neck carcinoma, particularly doing well in a new technique radiation for nasopharyngeal carcinoma, nasal cavity and ethmoid sinus tumors, and hypopharyngeal carcinoma. The research field includes nasopharyngeal carcinoma complicating dermatomyositis, visual function damage caused by radiation, clinical TNM stage for nasal cavity cancer, HPV infection in H&N carcinoma, and radiotherapy combining with biological therapy/molecular targeted therapy for H&N carcinoma. Prof. Hu has published more than 60 academic papers, undertaken numerous research projects, and brought up more than 10 post-graduates.
    Email huwh@sysucc.org.cn
    Phone (8620)87343608 Fax: (8620)87343608
    Research Interest(s)
    Nasopharyngeal carcinoma complicating dermatomyositis, visual function damage caused by radiation, clinical TNM stage for nasal cavity cancer, HPV infection in H&N carcinoma, and radiotherapy combining with biological therapy/molecular targeted therapy for H&N carcinoma.
    Education MD from Sun Yat-sen Medical college in 1976
    Publications

    1.胡伟汉,洪明晃,陈勇,闵华庆.鼻咽癌合并皮肌炎远期疗效分析.中华放射肿瘤学杂志,1993,2(1):12.

    2.胡伟汉,陈德林,闵华庆.鼻咽癌合并皮肌炎45例的临床研究.中华放射肿瘤学杂志,1995,4(3):169~170.

    3.胡伟汉,黄时洲,吴德正,等.鼻咽癌放射治疗对视路功能损伤的研究.中华放射肿瘤学杂志,1995,4(3):150~153.

    4.Wei-hanHu,De-ling Chen,Hua-Qing Ming.Study of 45 Cases of Nasopharygeal Carcinoma with Dermatomyotitis. American Journal of Clinical Oncology, 1996,19(1):35~38.

    5.胡伟汉主编导.常用放疗设备及其临床应用(教学录像片). CMB ( 美国中华医学基金会 )资助,1992,2.中华医学音像出版社发行.

    6.胡伟汉主编导.热疗原理与治癌(教学录像片) CMB ( 美国中华医学基金会 )资助,1994,11.中华医学音像出版社发行.

    7.胡伟汉,龙时先,周兰荪,等.鼻咽癌放射治疗对视诱发电位的早期影响.癌症,1997,16:(增刊)93~94.

    8.胡伟汉,王晓明,梁碧玲.原发性肝胆管癌蝶窦转移1例.癌症(增刊)1999,18:58 

    9.胡伟汉,陈 明,骆福添,等.IE期鼻腔非霍奇金氏淋巴瘤的治疗与预后.海南医学杂志,1999,12(6):93~94. 

    10.胡伟汉,余敏忠,龙时先,等.鼻咽癌放疗的视诱发电位研究.中国肿瘤临床与康复,2001,8:60-62 增刊.

    11.胡伟汉,陈明,骆福添,等.IE期鼻腔非霍奇金氏淋巴瘤预后的多因素分析.中华肿瘤杂志,2001,23(3):240-243.

    12.Wei-han Hu, Ming Chen, Ying Sun, et al. Multivariate Prognostic Analysis of Stage IE PrimaryNon-Hodgkin’s Lymphomas of the Nasal Cavity. American Journal of Clinical Oncology,2001,24(3):286-289. 

    13.胡伟汉,余敏忠,龙时先,等.放射线治疗鼻咽癌对视诱发电位改变的研究. 中华肿瘤杂志,2002,24(2)147-150.

    14.胡伟汉, 陈立新.鼻咽癌放射治疗技术新进展.广东医学,2002.23(4)333-334.

    15.胡伟汉,谢方云,陈德珠,等.60例上皮源性鼻腔癌的临床疗效分析.中华肿瘤杂志,2002.24(6)592-594

    16.胡伟汉,谢方云,赖越元,等.鼻腔腺样囊性癌的临床研究.中华放射肿瘤学杂志,2003.12(3)73-76.

    17.胡伟汉,谢方云,傅晓莹,等.23例原发性筛窦恶性肿瘤临床分析.中华放射肿瘤学杂志,2003.23(3)207-208.

    18.徐伯平,黄时洲,胡伟汉(通讯作者),等.中药防治鼻咽癌放疗致视后路损伤的研究,中国中西医结合杂志,2003,23(9):661-663.

    19.Hu Wei-han, Yu Min-zhong, Long Shi-xian, at al. Impairment of Optic Path due to Radiotherapy for Nasopharyngeal Cacinoma. DocumentaOphthalmologica, 2003. DocumentaOphthalmologica 107: 101–110.

    20.胡伟汉,谢方云,伍勇,等. 原发性鼻腔黑色素瘤24例临床分析.中华放射肿瘤学杂志,2004.13(1)8-11.

    21.聂大红,胡伟汉(通讯作者),高远红,等.鼻腔非霍奇金淋巴瘤的化学治疗及放射治疗.中华肿瘤杂志,2004.26(5)312-314.

    22.胡伟汉,谢方云,方盛华,等.87例鼻腔鳞癌的治疗与预后.中华放射肿瘤学杂志,2004.13(3):159-62.

    23.胡伟汉,谢方云,陈德珠,等.98例鼻腔癌的治疗与预后. 癌症, 2004. 11s(23): 1542-1545.

    24.胡伟汉,谢方云,方盛华,等.163例鼻腔恶性肿瘤治疗分析.中华肿瘤杂志,2005.27(2):65-69.

    25.潘 燚,胡伟汉(通讯作者),高 艺,等.鼻咽癌放疗后视野与诱发电位的改变.癌症,2005.24(6): 722-726.

    26.胡伟汉,张国义,刘立志,等.PET-CT与MRI诊断鼻咽癌淋巴结转移的对比研究,癌症,2005.24(7): 855-860.

    27.胡伟汉,赵雁梨,方盛华,等.鼻腔癌临床TNM新分期的研究.中华肿瘤杂志,2005.27(6):355-359.

    28.张国义,胡伟汉(通讯作者).124例上颌窦癌预后因素分析.中华放射肿瘤学杂志,2005.14(5): 378-382. 

    29.伍勇,胡伟汉(通讯作者),夏云飞,等. 192例鼻咽癌放疗后无瘤生存患者的生存质量分析.癌症,2005.24(11): 1376-1383. 

    30.张玉晶,胡伟汉(通讯作者),刘慧,等.鼻型NK/T细胞淋巴瘤的临床和预后分析, 中华肿瘤杂志,2006,28(1):50-53.

    31.潘燚,胡伟汉(通讯作者),谢丹,等. 脑胶质瘤组织中Survivin细胞核表达与预后的关系,癌症,2006,25(5):635-639.

    32.张国义,刘立志,胡伟汉(通讯作者),等.鼻咽癌咽后淋巴结转移磁共振诊断标准的研究,中华医学杂志,2006,86(18):1265-1267.

    33.张国义,胡伟汉(通讯作者),刘立志,等. PET/CT与MRI在鼻咽癌淋巴结转移诊断和N分期中的比较研究.中华肿瘤杂志,2006,28(5):381-384.

    34.秦海燕,胡伟汉(通讯作者),李小芳,等. 原发性扁桃体NHL临床特点和预后分析,现代肿瘤医学,2007,15 (1): 15-18. 

    35.梁颖,高剑铭,胡伟汉(通讯作者),等.诱导化疗联合同期放化疗对局部晚期鼻咽癌的远期疗效,癌症,2007,26(8):885-889. 

    36.秦海燕,胡伟汉(通讯作者),张晓实,等.细胞因子诱导杀伤细胞联合白介素-2治疗头颈部肿瘤近期疗效观察,广东医学, 2007,28(4):560-562. 

    37.秦海燕,胡伟汉(通讯作者),张晓实,等.CIK细胞联合白介素- 2对鼻咽癌病人免疫功能及EB病毒指标的影响. 现代肿瘤医学,2007(12):1747-9.

    38.Wu Yong, Hu wei-han(通讯作者), Xia yun-fei, et al. Quality of life of nasopharyngeal carcinoma survivors in Mainland China, Quality of Life Research,2007,16:65-74.

    39.潘燚,胡伟汉(通讯作者),谢丹,等.生存素在细胞核及细胞质中的表达与脑胶质瘤患者预后的关系.中华医学杂志,2007,87(5):325-329.(暂不提供全文下载)

    40.徐韬,胡伟汉(通讯作者),高远红,等. 3-(5'羟甲基-2'呋喃基)-1苯甲基吲唑联合放疗治疗Lewis移植瘤小鼠的实验研究.肿瘤研究与临床,2008,20(2): 76-79,86. 

    41.徐韬,胡伟汉(通讯作者).低氧诱导因子与肿瘤放射治疗. 国际肿瘤学杂志, 2008, 35(3): 173-176. 

    42.徐韬,胡伟汉(通讯作者).抑制新生血管联合放射治疗的机制探讨及存在问题. 实用肿瘤学杂志,2008,22(2):155-159.

    43.徐韬,胡伟汉(通讯作者),伍国号,等.151例下咽鳞癌的治疗方式与预后.中国肿瘤临床,2008,35(11): 606-610.

    44.王芳,徐 韬,胡伟汉(通讯作者),等. 原发舌根非霍奇金淋巴瘤的临床分析. 中国肿瘤临床,2008,19(35):1106-1108 .

    45.王芳,王汉渝,胡伟汉(通讯作者),等. 调强放疗联合西妥昔单抗及顺铂治疗晚期鼻咽癌.中国肿瘤生物治疗杂志,2008,15(5):489-493.

    46. 伍勇,胡伟汉(通讯作者),毛平,等. SF-36中文版健康状况调查表评价鼻咽癌疗后长期存活者适用性研究.中华放射肿瘤学杂志,2010,19(3):201-204.

    47.胡伟汉.对鼻咽癌诊治现状的若干看法.肿瘤研究与临床,2010,22(8):505-508. 

    48.张国义,魏伟宏,胡伟汉(通讯作者),等.鼻咽癌咽后淋巴结转移分布规律的研究.肿瘤研究与临床,2010,22(8):509-511. 

    49.伍勇,刘国龙,胡伟汉(通讯作者),等.生存质量对鼻咽癌长期生存预后的影响. 肿瘤研究与临床,2010,22(8):523-525. 

    50.葛楠,林焕新,胡伟汉(通讯作者),等.117例鼻咽癌适形调强放射治疗的预后研究.肿瘤研究与临床,2010,22(8):530-533. 

    51.王顺兰,陈明远,胡伟汉(通讯作者),等.鼻咽癌放疗后第二原发舌鳞癌35例. 肿瘤研究与临床,2010,22(8):534-536. 

    52. Nan Ge, …, Wei-Han Hu(通讯作者), Tiebang Kang. Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. Journal of Translational Medicine,2010,8:94

    53. 张国义,魏伟宏,胡伟汉(通讯作者),等.正电子发射断层显像-计算机断层显像在鼻咽癌远处转移诊断中的应用价值.肿瘤研究与临床,2011,23(5):294-298. 

    54. Ting Jin, Wei-Han Hu(通讯作者), Li-Bing Guo, et al. Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma. Chinese Journal of Cancer,2011,30(7):482-489.

    55. 金厅,王芳,胡伟汉(通讯作者),等.HIF-1α与VEGF在下咽鳞癌中的表达及其临床意义.中华放射肿瘤学杂,2011,20(5):385-389. 

    56. Ting Jin,,Huan-XinLin,HuiLin,Li-Bing Guo, Nan Ge,Xiu-Yu Cai,RuiSun,Wen-KuanChen,Qiu-Li Li,Wei-Han Hu(通讯作者),Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study.Journal of Translational Medicin,2012,10:64

    57. Zeng R, Dai Q, Peng Z, Cai P, Hu W. Prediction of occult cervical lymph node metastasis in clinically negative supraglottic squamous cell carcinoma. Head Neck Oncol. 2012 Oct 27;4(3):69. 

    58. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012; 138: 1717-25.

    59. Lin H, linHX, Hu Wei-Han(通讯作者)et al. Chemotherapy plus radiotherapy makes curability a possibility for NPC patients with distant metastases at diagnosis. Head Neck Oncology. 2013 Jan 04;5(1):1

    60. Lin H, linHX, HuWei-Han(通讯作者)et al.Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncology. 2013 May 15;8(1):121.

    61. Cai X, Hu W, Zhang B et al. Genotyping of IL-8-251 T>A yields prognostic information in patients with gastric carcinoma. Biomarkers. 2013 Aug28;18(7):559-564

    62. 王洪智, 胡伟汉. Hpv相关头颈部肿瘤分子表型及对放化疗敏感性的影响. 癌症进展. 2014; 12(1):54-58.

    63. Wang H, ...Hu Wei-Han. P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects. Cancer Sci 2013; 104: 1553-59

    64. Wei WH, Huang ZL, Li SE, Chen HM, Lin L, Zhang GY, Lu QX Wu YF, *Hu WH, *Xu T. Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area. Oncology Research and Treatment.

     

    Last Updated on: August 2014
    Lixia Lu
    Title Associate Professor
    Profile

    2002-Present: Associate Professor, Department of Radiation Oncology, Tumor Hospital of Sun Yat-sen University , Guangzhou 510060,China.

    1989-2002: Attending Doctor, Department of Radiology, Tumor Hospital of Sun Yat-sen University , Guangzhou 510060,China.

    Email lulx@sysucc.org.cn
    Phone 0086-020-87343663(Work), 0086-13688898966(China)
    Research Interest(s)

    • Oriented in radiation and biological research in Head and Neck cancer

    • 20 years’ experience in imaging diagnosis and 3DCRT & IMRT treatment of oncology

    Education

    2005~2008:Sun Yat-sen University, China, Oncology, Ph.D;

    1986~1989:Sun Yat-sen University of Medical Sciences China, Oncology, M.D;

    1979~1984:Jiangxi Medical College, China, Medicine, M.D;

    Publications

    • Results of a Phase 2 Study Examining the Effects of Omitting Elective Neck Irradiation to Nodal Levels IV and Vb in Patients With N0-1 Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. Volume 85, Issue 4, 15 March 2013, Pages 929~934;

    • Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma using Intensity-modulated Radiotherapy. Clinical Oncology, Volume 24, Issue 8, October 2012, Pages 569~576;

    • Nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. European Journal of Cancer, Volume 48, Issue 18, December 2012, Pages 3422~3428;

    • Intensity-Modulated Radiation Therapy Reduces Radiation-Induced Trismus in Patients With Nasopharyngeal Carcinoma. A Prospective Study With >5 Years of Follow-Up, Cancer, Volume 117, Issue 13, pages 2910~2916;

    • Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: Characteristics of long-term survivors after concurrent chemoradiotherapy. Radiotherapy and Oncology, Volume 99, Issue 2, May 2011, Pages 181~186;

    • Values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.,Journal of Translational Medicine 2009, 7:73

    • Outcome of Fractionated Stereotactic Radiotherapy for 90 Patients with Locally Persistent And Recurrent Nasopharyngeal Carcinoma, Int J. Radiat Oncol Biol Phys. Nov, 2007

    • The Target Volume Definition and the Pattern of Failure in Patients Receiving IMRT for Nasopharyngeal Carcinoma, Int J. Radiat Oncol Biol Phys, Nov, 2006

    • Peirradiation for locally recurrent nasopharyngeal carcinoma using IMRT clinical outcome and prognostics factors. 2005,10, Int. J. Radiation Oncology Bio. Phys

    • Initial study of the target volume delineation for Nasopharyngeal Carcinoma treated with radiotherapy. Chin J Radiat Oncol,2005.03.15; 14(2): 81~85

    • An overview of diagnostic imaging for liver cancer. Chinese Journal of Hepatology, 2003,Vol. 11 No.9

     

    Last Updated on: August 2014

    Fei Han
    Title Associate Professor
    Profile
    Dr. Fei Han is associate professor of the department of radiation oncology, at Sun Yat-sen University Cancer Center. Dr. Han obtained his Bachelor degree in Medicine (equivalent to MD in the US) at Jiangxi Medical College in 1994, then gained a Medical Master's degree and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2012, respectively. Dr. Han has made great progress in clinical radiotherapy skills, especially head & neck cancer and nasopharyngeal carcinoma. He is also active in the research of recurrent nasopharyngeal carcinoma. Dr. Han has published more than 110 research papers.
    Email hanfei@sysucc.org.cn
    Phone 86-20-87343030
    Research Interest(s)

    1. Focus on improving the therapeutic ratio of radiation therapy for Head & Neck cancer. 

    2. Study novel radio biological knowledge about IMRT especially the injure prevention of normal tissues.

    3. Comprehensive therapy in nasopharyngeal carcinoma, especially in recurrent nasopharyngeal carcinoma.

    Education

    2005.09-2012.06 Sun Yat-Sen University, Guangzhou, Guangdong, China.Ph.D of Oncology awarded.

    1997.09-2000.06 Sun Yat-sen University of Medical Science, Guangzhou, Guangdong, China.Master degree of Radiation Oncology awarded.

    1989.08-1994.06 Jiangxi medical college, Nanchang, Jiangxi, China.Bachelor degree of clinical medicine awarded.

    Publications

    1. Tian YM, Tian YH,Zeng L, Liu S, Guan Y, Lu T,Han F. Prognostic modle for survival of local recurrent nasopharyngeal carcinoma with internsity-modulated radiotherapy. Brit J of Cancer.2014,110(2)297-303.1111. (corresponding author)

    2. Tian YM, Zeng L, Wang FH, Liu S, Guan Y, Lu TX, Han F. Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment. Radiation Oncology 2013, 8:272. (corresponding author)

    3. Fei Han, Chong Zhao, Shao-min Huang, Li-xia Lu, Ying Huang, Xiao-Wu Deng , Wei-Yuan Mai, Bin S. Teh, E. Brian Butler, Tai-Xiang Lu. Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent NasopharyngeaCarcinoma using Intensity-modulated Radiotherapy. Clinical Oncology. 2012,24(9): 569-576.

    4. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol. Biol Phys, 2009,74(4):1070-1076.(joint first author)

    5. Han F, Zhao C, Xiao WW, Lu LX, Wu SX, Huang SM, Lu TX. Long-term results of a phase II study of concurrent chemotherapy and IMRT for Locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol. Biol Phys, 2009,75(3s):s644.

    6. Sheng-fa Su, Fei Han, Chong Zhao, Chun-yan Chen, Wei –wei Xiao, Jia-xin Li, Tai-xiang Lu. Long-term outcome of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy along. Int J Radiat Oncol Biol Phys, 2012, 82(1): 327–333.

    7. Chen CY, Han F, Zhao C, Lu LX, Sun Y, Liu XF and LU TX. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. British Journal of Radiology. 2009,82:452-458.

     

    Last Updated on: August 2014
    Qiaoqiao Li
    Title Associate Professor
    Profile
    Dr. Qiaoqiao Li is an associate professor of radiation oncology at Sun Yat-sen University Cancer Center. Dr. Li obtained her Bachelor and PhD at Sun Yat-sen University, P. R. China in 2000 and 2009, respectively. After she got the MD, she joined the Department of Radiation Oncology at Sun Yat-sen University Cancer Center as a resident in July 2000. She got the attending and associate professor position of Radiation Oncology in 2005 and 2013 respectively. From Feb 2013 to August 2014, she was trained as a visiting scientist of Radiation Oncology at MD Anderson Cancer Centre in Houston, Texas, U.S. and majored in thoracic cancer radiation therapy, especially the stereotactic ablative radiation therapy for non-small cell lung cancer.
    Email liqq@sysucc.org.cn
    Phone
    Research Interest(s) Radiation therapy or chemoradiation therapy for lung cancer and esophageal cancer
    Education

    M.B., 1995.9-2000.7 Sun-Yat-Sen University, Guangzhou, P.R. China

    M.S., 2003.9-2006.9 Cancer Center, Sun-Yat-Sen University, Guangzhou, P.R. China, 

    Ph. D of Radiation Oncology, 2006.9-2009.12  Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China.

    Publications  Li QQ, Swanick CW, Pamela KA, et al. Exploration of stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: what are the indication? Radiother Oncol, 2014 (accepted)

     Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys, 2014, 88: 1120-1128.

     Lei Z, Li QQ (equal contributors), Rui Z, et al. The overexpression of IGFBP-3 is involed in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumor Biology, 2012, 33:1115-1123. 

     Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010, 23(3):253-9.

     Li QQ, Hu YH, Liu MZ, Liu H, Huang Y, He ZY, Lin HX. Results of radiotherapy with concurrent docetaxel and cisplatin in unresectabel esophageal carcinoma. Chin J Radiat Oncol, 2009, 18(5): 379-382.

     Li QQ, Liu MZ, Hu YH, Liu H, Huang Y, Cui NJ. Clinical Value of Barium Swallow in Observing Esophageal Tumor Regression during Radiotherapy. Chin J Cancer, 2003, 25(6):723-727.

     

     
    Last Updated on: August 2014
    Chen Lixin
    Title Research associate
    Profile
    Email
    Phone
    Research Interest(s)
    Education
    Publications
    Xi Mian
    Title Attending Physician
    Profile
    Dr. Mian Xi is attending physician of radiation oncology at Sun Yat-sen University Cancer Center. Dr. Xi obtained her Bachelor in Medicine (equivalent to MD in the US) at Zhengzhou University, P. R. China in 2004. Then, she obtained her master's and doctor's degrees at Sun Yat-sen University in 2007 and 2013, respectively. Her research interests in radiotherapy are focused on thoracic and abdominal malignancies.
    Email ximian@sysucc.org.cn
    Phone 020-87343385
    Research Interest(s)
    Radiotherapy for thoracic and abdominal malignancies; Radiation-induced malignancies (RIM) in patients with nasopharyngeal carcinoma.
    Education

    9/2010−6/2013 Cancer Center, Sun Yat-sen University, PhD, Oncology 

    9/2004−7/2007 Cancer Center, Sun Yat-sen University, MS, Oncology 

    9/1999−7/2004 Zhengzhou University, MD, Clinical Medicine

    Publications

    1. Xi M, Liu SL, Zhao L, Shen JX, Zhang L, Zhang P, Liu MZ. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013; 8(12): e84586. 

    2. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013; 8(5): e63864. 

    3. Zhang P, Xi M (co-first author), Zhao L, Li QQ, He L, Liu S, Shen J, Liu MZ. Unilateral cervical nodal metastasis is an independent prognostic factor for esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective study. PLoS One. 2014; 9(6): e101332. 

    4. Xi M, Zhang L, Li QQ, Zhao L, Zhang R, Liu MZ. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162. 

    5. Zhang L, Xi M (co-first author), Deng XW, Li QQ, Huang XY, Liu MZ. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012; 53(5): 769-76.

     6. Xi M, Zhang L, Liu MZ, Deng XW, Huang XY, Liu H. Dosimetric analysis of respiratory gated radiotherapy for hepatocellular carcinoma. Med Dosim. 2011; 36(2): 213-218. 

    7. Xi M, Zhang L, Liu MZ, Li QQ. Radiation-induced malignancy following definitive radiotherapy for nasopharyngeal carcinoma. Ann Oncol. 2012; 23S(9): 1048p. (Abstract)

     8. Xi M, Liu MZ, Wang HX, Cai L, Zhang L, Xie CF, Li QQ. Radiation-induced sarcoma in patients with nasopharyngeal carcinoma: a single-institution study. Cancer. 2010; 116(23): 5479-5486. 

    9. Xi M, Liu MZ, Zhang L, Li QQ, Huang XY, Liu H, Hu YH. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259. 

    10. Xi M, Liu MZ, Zhang L, et al. Analysis of abdominal organ mobility using four-dimensional CT. Int J Radiat Oncol Biol Phys. 2009; 75S(3): 288. (Abstract) 

    11. Xi M, Liu MZ, Deng XW, Zhang L, Huang XY, Liu H, Li QQ, Hu YH, Cai L, Cui NJ. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol. 2007; 84(3): 272-278.

    Linglong Tang
    Title Attending Physician
    Profile

    Dr. Tang obtained her Bachelor and Master's degree in Medicine from Sun Yat-sen University of Medical Sciences, P. R. China in 2002 and 2006, respectively. Her research interests focus on radiotherapy and multidisciplinary treatment for nasopharyngeal cancers. As the 5th Contributor, she won Second Prize of National Science and Technology Progress Award, National Office for Science and Technology Awards in 2009.

    Email tangll@sysucc.org.cn
    Phone 02087343096
    Research Interest(s) Radiotherapy and multidisciplinary treatment in nasopharyngeal cancers: treatment outcome; prognostic factors; pretreatment stage criteria ; treatment toxicities and quality of life
    Education

    ①M.B., 1997.9-2002.7 Sun-Yat-Sen University, Guangzhou, P.R. China; M.S., 

    ②2003.9-2006.7Cancer Center, Sun-Yat-Sen University, Guangzhou, P.R. China; 

    ③Ph. D of Radiation Oncology, 2011.9-present Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China; 

    ④ Residency (Radiation Oncology), 2006.7-2009.11 ⑤Attending Physician (Radiation Oncology), 2009.12-Present

    Publications

    ①Tang LL, Sun Y, Mao YP, Chen Y, Li WF, Chen L, Liu LZ, Lin AH, Li L, Ma J . Prognostic Value of Parapharyngeal Extension in Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy.Radiother Oncol. 2014;110(3):404-8 

    ②Tang L, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J.Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010;257(1):151-7. 

    ③Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, Liao X, Lin A, Liu M, Li L, Ma J.The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging.Cancer. 2009;115(3):680-8.

    ④Tang L, Li L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, Liao X, Tian L, Lin A, Liu M, Ma J. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging : prognostic value and staging categories. Cancer. 2008;113(2):347-54.

Where are we | Contact us

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.